PERSONAL INFORMATION
Name: Wen Cui
Gender: Male
Title: Associate professor
CONTACT INFORMATION
Email: 190559@cqmu.edu.cn
Address: Institute of Life Sciences
No.1 Yixueyuan Road, Yuzhong District
Chongqing,China
Phone: +86-13512082235
EDUCATION EXPERIENCE
PhD Tianjin University (2019)
MS Tianjin University (2014)
WORKING EXPERIENCE
Postdoctoral Fellow Chongqing Medical University (2023)
RESEARCH INTERESTS
Dr Wen’s research primarily focuses on structural and biochemical studies of proteins that play a crucial role in the interactions between pathogens and hosts He is specifically interested in: 1. The structure and function of critical drug targets for important pathogens; 2. The molecular mechanisms of the virus suppression by host antiviral factors and viral immune evasion.
PUBLICATIONS
1.Wen Cui#, Haojun Huang#, Yinkai Duan#, Zhi Luo, Haofeng Wang, Tenan Zhang, Henry C. Nguyen, Wei Shen, Dan Su, Xi Li, Xiaoyun Ji*, Haitao Yang*, Wei Wang*. Crystal structure of monkeypox H1 phosphatase, an antiviral drug target. Protein Cell, 2023, 14(6):469-472.
1.Wen Cui#, Elisabeth Braun#, Wei Wang#, Jinhong Tang#, Yanyan Zheng#, Benjamin Slater, Na Li, Cheng Chen, Qingxiang Liu, Bin Wang, Xiu Li, Yinkai Duan, Yunjie Xiao, Ruijiao Ti, Dominik Hotter, Xiaoyun Ji, Lei Zhang, Jun Cui, Yong Xiong, Daniel Sauter*, Zefang Wang*, Frank Kirchhoff*, Haitao Yang*. Structural basis for GTP-induced dimerization and antiviral function of guanylate-binding proteins. PNAS, 2021, 118(15):e2022269118.
2.Mengmeng Lin#, Wen Cui#, Hongliang Tian#, Yan Zhang, Chen Chen, Xiaoyun Yang, Heng Chi, Zhongyu Mu, Cheng Chen, Zefang Wang, Xiaoyun Ji*, Haitao Yang*, Zhi Lin*. Structural Basis of Zika Virus Helicase in RNA Unwinding and ATP Hydrolysis. ACS Infect Dis, 2021, 8(1): 150-158.
3.Wei Wang#,*, Wen Cui#, Haitao Yang*. Toward an accurate mechanistic understanding of Wolbachia-induced cytoplasmic incompatibility. Environ Microbiol, 2022, 24(10): 4519-4532.
4. Wen Cui, Kailin Yang*, Haitao Yang*. Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19, Front Mol Biosci, 2020, 7: 616341.
